Treatment outcome of transcatheter arterial chemoinfusion according to anticancer agents and prognostic factors in patients with advanced hepatocellular carcinoma (TNM stage IVa)

Yonsei Medical Journal

Volumn 45, Issue 5, 2004, Pages 847-858

  Ahn, Sang Hoon ^a   Han, Kwang Hyub ^a   Park, Jeong Youp ^a   Youn, Young Hoon ^a   Moon, Chang Mo ^a   Lee, Kwan Sik ^a   Chon, Chae Yoon ^a   Moon, Young Myoung ^a   Lee, Do Yun ^a   Lee, Jong Tae ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; Prognostic factors; Transcatheter arterial chemoinfusion; Treatment outcome

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; IODINATED POPPYSEED OIL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGE; AGED; ALBUMIN BLOOD LEVEL; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHI SQUARE TEST; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FEVER; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PORTAL VEIN THROMBOSIS; PROGNOSIS; RISK ASSESSMENT; STUDENT T TEST; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 9144240530     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2004.45.5.847     Document Type: Article

References (43)

1. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
2. Bismuth H, Houssin D, Ornowski J, Meriggi F. Liver resection in cirrhotic patients: a Western experience. World J Surg 1986;10:311-7.
3. Bruix J, Cirera I, Calvet X, Fuster J, Bru C, Ayuso C, et al. Surgical resection and survival in Western patients with hepatocellular carcinoma. J Hepatol 1992; 15:350-5.
4. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996;77:2217-22.
5. Liu CL, Fan ST. Nonresectional therapies for hepatocellular carcinoma. Am J Surg 1997;173:358-65.
6. Lehnert T, Herfarth C. Chemoembolization for hepatocellular carcinoma. What, when, and for whom? Ann Surg 1996;224:1-3.
7. Lee JH, Chon CY, Ahn SH, Moon BS, Kim JH, Paik YH, et al. An ischemic skin lesion after chemoembolization of the internal mammary artery in a patient with hepatocellular carcinoma. Yonsei Med J 2001;42:137-41.
8. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27: 1578-83.
9. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998;29:129-34.
10. Adachi E, Matsumata T, Nishizaki T, Hashimoto H, Tsuneyoshi M, Sugimachi K. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer 1993; 72:3593-98.
11. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: Diagnosis and Treatment. Gastroenterology 2002;122: 1609-19.
12. Eggel H. Ueber das primare Carcinoma der Leber. Beitr z Path Anat u z allgem Pathol 1901;30:506-604.
13. Japan Society for Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 1993;28:101.
14. Kajanti M, Rissanen P, Virkkunen P, Franssila K, Mantyla M. Regional intra-arterial infusion of cisplatin in primary hepatocellular carcinoma; a phase II study. Cancer 1986;58:2386-98.
15. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma-a randomized controlled trial. Gastroenterology 1988;94:453-6.
16. Imaoka S, Sasaki Y, Shibata T, Fujita M, Kasugai H, Kojima J, et al. A preoperative chemoembolization therapy using lipiodol, cisplatin, and gelatin sponge for hepatocellular carcinoma. Cancer Chemother Pharmacol 1989;23 Suppl:126.
17. Kasugai H, Kojima J, Tatsuta M, Okuda S, Sasaki Y, Imaoka S. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989;97:965-71.
18. Vetter D, Wenger JJ, Bergier JM, Doffoel M, Bockel R. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a western comparative study in 60 patients. Hepatology 1991;13:427-33.
19. Falkson G, Ryan LM, Johnson LA, Simson IW, Coetzer BJ, Carbone PP, et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: an ECOG study. Cancer 1987;60: 2141-5.
20. Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, Matsunaga Y. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin-2 in patients with unresectable hepatocellular carcinoma. Hepatology 1989;10:349-53.
21. Shiina S, Tagawa K, Unuma T. Percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma. AJR 1990;154:947-51.
22. Dhir V, Swaroop VS, Mohandas KM. Combination chemotherapy and radiation for palliation of hepatocellular carcinoma. Am J Clin Oncol 1992;15:304-7.
23. Jenkins RL, Pinson CW, Stone MD. Experience with transplantation in the treatment of liver cancer. Cancer Chemother Pharmacol 1989;23 Suppl:104-9.
24. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997;79:1890-6.
25. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88: 1986-91.
26. Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, et al. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002;80:143-8.
27. Lai Y-C, Shih C-Y, Jeng C-M, Yang S-S, Hu J-T, Sung Y-C, et al. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with tumor thrombosis of the portal vein. World J Gastroenterol 2003;9:2666-70.
28. Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. Am J Roentgenol 1995;165:315-21.
29. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK. Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepato-Gastroenterology 1999;46:1122-5.
30. Yasui M, Nonami T, Kurokawa T, Nakao A, Harada A, Hashimoto S, et al. Effects of hepatic arterial infusion chemotherapy on unresectable or recurrent hepatocellular carcinoma. Cancer Chemother Pharmacol 1994; 33 Suppl:S139-41.
31. Kalayci C, Johnson PJ, Raby N, Metivier EM, Williams R. Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. J Hepatol 1990;11:349-53.
32. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prespective randomized trial. Cancer 1988;62:479-83.
33. Doci R, Bignami P, Bozzetti F, Bonfanti G, Audisio R, Colombo M. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 1988;61:1983-7.
34. Okuda S. Transcatheter arterial embolization for advanced hepatocellular carcinoma: the controversy continues. Hepatology 1998;27:1743-4.
35. Bayraktar Y, Balkanci F, Kayhan B, Uzunalimoglu B, Gokoz A, Ozisik Y, et al. A Comparison of chemoembolization with conventional chemotherapy and symptomatic treatment in cirrhotic patients with hepatocellular carcinoma. Hepato-Gastroenterology 1996;43: 681-7.
36. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-4.
37. Groupe D'etude et de traitement du carcinome hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-61.
38. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 1997;79:2087-94.
39. Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer 1991;68:2150-4.
40. Mondazzi L, Bottelli R, Brambilla G, Rampoldi A, Rezakovic I, Zavaglia C, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognosis factors. Hepatology 1994;19:1115-23.
41. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207-15.
42. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged?: Validation of a new prognostic system. Cancer 2000;89:2266-73.
43. The cancer of the liver Italian program (CLIP) investigations. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31:840-5.